当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.

Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.

Abstract：

:Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine and cyclophosphamide (BEAC). The 5-year Kaplan-Meier event-free survival (EFS) for the entire cohort was 32% (95% confidence interval; 18-45%) with a median follow-up of 3.6 years (range 7 months-7.6 years). The most significant predictor of improved survival was the presence of minimal disease (defined as all areas < or =2 cm) at the time of transplant: the 5 years EFS was 46 vs 10% for patients with bulky disease (P = 0.0002). Other independent predictors identified by step-wise regression analysis included the presence of non-refractory disease and the administration of post-transplant involved-field radiotherapy (XRT). Treatment-related mortality occurred in 13 of 70 patients: nine patients (13%) died within the first 100 days, mainly from cardiopulmonary toxicity. However, only one of 24 patients (4%) transplanted during the last 4.5 years died from early treatment-related complications. While high-dose therapy followed by autotransplantation led to long-term EFS of 50% for patients with favorable prognostic factors, a substantial proportion of patients relapsed, indicating that new therapeutic strategies are needed.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

doi

10.1038/sj.bmt.1701325

subject

Has Abstract

pub_date

1998-08-01 00:00:00

pages

265-71

issue

3

eissn

0268-3369

issn

1476-5365

journal_volume

22

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Ethical problems in bone marrow transplantation in children.

    abstract：:The medical staff caring for children with hematological or oncological diseases is often faced with delicate ethical and, at times, legal problems. Although many of these are common to other branches of pediatrics where patients are children lacking decision-making capacity, others, such as bone marrow transplantatio...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Massimo L

    更新日期：1996-11-01 00:00:00

  • Early iron reduction programme for thalassaemia patients after bone marrow transplantation.

    abstract：:Thirty thalassaemia patients received iron reduction starting at around 3 months post transplant. Sixteen received desferrioxamine and nine had phlebotomy, five patients had desferrioxamine followed by phlebotomy. The desferrioxamine group had higher serum ferritin levels at the start of iron reduction as compared to ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1702212

    authors： Li CK,Lai DH,Shing MM,Chik KW,Lee V,Yuen PM

    更新日期：2000-03-01 00:00:00

  • Use of the BCR probe to demonstrate extramedullary recurrence of CGL with a T cell lymphoid phenotype following bone marrow transplantation.

    abstract：:A case of Philadelphia chromosome (Ph1) positive chronic granulocytic leukemia (CGL) is described in which the patient underwent successful treatment with supralethal chemoradiotherapy and allogeneic bone marrow transplantation (BMT) after transformation to blast crisis. Supraclavicular adenopathy developed 5 months a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Giannone L,Whitlock JA,Kinney MC,Wolff SN,Dev VG

    更新日期：1988-11-01 00:00:00

  • Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.

    abstract：:G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1701795

    authors： Piccirillo N,Sica S,Laurenti L,Chiusolo P,La Barbera EO,Sorà F,Leone G

    更新日期：1999-06-01 00:00:00

  • A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation.

    abstract：:Allogeneic hematopoietic stem cell transplantation (ASCT) and its conditioning with chemoradiotherapy often results in liver toxicity, the most severe form being veno-occlusive liver disease (VOD). N-acetyl-L-cysteine (NAC), an antioxidant glutathione precursor, may provide protection from liver toxicity. Patients wit...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1705969

    authors： Barkholt L,Remberger M,Hassan Z,Fransson K,Omazic B,Svahn BM,Karlsson H,Brune M,Hassan M,Mattsson J,Ringdén O

    更新日期：2008-05-01 00:00:00

  • Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion complicating stem cell transplantation.

    abstract：:Hyponatremia is a common electrolyte disorder in hospitalized patients. Although there are a few case reports of hyponatremia following stem cell transplantation (SCT), no reports concerning the incidence are currently available. We describe the occurrence of hyponatremia and the syndrome of inappropriate secretion of...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704688

    authors： Kobayashi R,Iguchi A,Nakajima M,Sato T,Yoshida M,Kaneda M,Suzuki Y,Mino E,Kuroki F,Kobayashi K

    更新日期：2004-12-01 00:00:00

  • Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis.

    abstract：:We evaluated 120 leukapheresis procedures (93 patients), in order to detect clinical factors that influence the efficiency of CD34+ collection using Cobe Spectra trade mark cell separators. Hematocrit was >27% and platelet count >30 000/microl in >95% of patients. Platelet transfusions were given if the postprocedure ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704034

    authors： Sarkodee-Adoo C,Taran I,Guo C,Buadi F,Murthy R,Cox E,Lopez R,Westphal S,Shope S,O'Connell B,Wethers L,Meisenberg B

    更新日期：2003-05-01 00:00:00

  • Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation.

    abstract：:Acute inflammatory demyelinating polyneuropathy (AIDP) appeared in two patients following allogeneic bone marrow transplantation (BMT). In one transplanted patient (but not in the donor) T cells were sensitized against peripheral nervous system myelin. This could reflect a change in the T cell repertoire in a differen...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Eliashiv S,Brenner T,Abramsky O,Shahin R,Agai E,Naparstek E,Steiner I

    更新日期：1991-10-01 00:00:00

  • A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

    abstract：:Intrabone marrow cord blood transplantation (IB-CBT) was proposed as a promising treatment modality to improve hematological recovery. However, clinical advantages of IB-CBT over conventional IV CBT have been unclear. We conducted a prospective single-center trial of IB-CBT to evaluate its safety and superiority in te...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.319

    authors： Kurita N,Gosho M,Yokoyama Y,Kato T,Obara N,Sakata-Yanagimoto M,Hasegawa Y,Uchida N,Takahashi S,Kouzai Y,Atsuta Y,Kurata M,Ichinohe T,Chiba S

    更新日期：2017-04-01 00:00:00

  • Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease.

    abstract：:A 16-month-old girl diagnosed with osteopetrosis underwent an unrelated, partially matched (with major mismatch at A locus) cord blood stem cell transplant. Twelve months later she developed severe acute autoimmune hemolytic anemia (AIHA). Immunophenotype analysis of lymphocyte subsets 8 months post transplant showed ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703087

    authors： Sevilla J,González-Vicent M,Madero L,Díaz MA

    更新日期：2001-07-01 00:00:00

  • Results of single and double autografts for high-risk neuroblastoma patients.

    abstract：:Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factor...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Kawa-Ha K,Yumura-Yagi K,Inoue M,Park DY,Okamura T,Yasui M,Oota H,Sakata N,Yoneda M,Imura K

    更新日期：1996-06-01 00:00:00

  • Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease.

    abstract：:HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0145-1

    authors： Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

    更新日期：2018-09-01 00:00:00

  • High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results.

    abstract：:We report long-term results of high-dose cyclophosphamide, etoposide and carboplatin with ABMT in 20 patients with metastatic breast cancer. Median age of the group was 41 years, ECOG performance status = 0 in 18 patients and 1 in two patients. Twelve patients had received adjuvant chemotherapy. Predominant sites of m...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701173

    authors： Baker WJ,Vukelja SJ,Burrell LM,Lee N,Perry JJ

    更新日期：1998-04-01 00:00:00

  • Predictors of non-compliance in autologous hematopoietic SCT patients undergoing out-patient transplants.

    abstract：:Non-compliance has received significant attention in medicine, yet few studies have examined its correlates in autologous hematopoietic SCT (AHSCT) patients. This study examined predictors of non-compliance in a sample of 151 AHSCT patients treated in an outpatient setting. Before AHSCT, participants completed a valid...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2011.129

    authors： Mumby PB,Hurley C,Samsi M,Thilges S,Parthasarathy M,Stiff PJ

    更新日期：2012-04-01 00:00:00

  • Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).

    abstract：:High-dose cyclophosphamide (HD-CY; 7 g/m2) was administered to patients suffering from high risk multiple myeloma (MM). The safety of this procedure, the recirculation and collection of peripheral blood stem cells (PBSC) and the effect of rhGM-CSF and HD-CY were studied. Group I patients (n = 21) were treated with HD-...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Boiron JM,Marit G,Fabéres C,Cony-Makhoul P,Foures C,Ferrer AM,Cristol G,Sarrat A,Girault D,Reiffers J

    更新日期：1993-07-01 00:00:00

  • Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.

    abstract：:On January 20, 2020, the first patient with coronavirus disease 2019 (COVID-19) in the United States of America was diagnosed in Washington state, which subsequently experienced rapidly increasing numbers of COVID-19 cases, hospitalizations, and deaths. This placed the Seattle Blood and Marrow Transplant Program at Fr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/s41409-020-01068-x

    authors： Ueda Oshima M,Sandmaier BM,Petersdorf E,Flowers ME,Hill GR,Lee SJ,Appelbaum FR,Carpenter PA,Baker KS,Connelly-Smith L,McCool A,Elgar S,Pergam SA,Liu C,Stewart FM,Mielcarek M

    更新日期：2020-09-26 00:00:00

  • Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.

    abstract：:High relapse rates during the first year after autologous stem cell transplantation (ASCT) for multiple myeloma or non-Hodgkin lymphoma are due to the failure of high-dose chemotherapy to eradicate minimal residual disease. Post-ASCT immunorecovery studies have shown that quantities of natural killer (NK) cells return...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703203

    authors： Porrata LF,Inwards DJ,Lacy MQ,Markovic SN

    更新日期：2001-10-01 00:00:00

  • Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS).

    abstract：:Severe veno-occlusive (VOD) disease is a major cause of morbidity and mortality in allogeneic bone marrow transplant recipients, and new approaches in managing patients who develop serious VOD is needed. In this report, we describe a patient who underwent transjugular intrahepatic portosystemic stent-shunt (TIPS) for ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Lévy V,Azoulay D,Rio B,Vincent F,Rabbat A,Hunault M,Bazarbachi A,Delmer A,Zittoun R

    更新日期：1996-08-01 00:00:00

  • Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study.

    abstract：:Liver dysfunction is a common problem in BMT recipients and it is important to determine the etiology in order to institute appropriate therapy. The purpose of this study was to evaluate the possible causes of liver dysfunction during the first post-transplant year in BMT recipients and to identify a possible relation...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702453

    authors： Kim BK,Chung KW,Sun HS,Suh JG,Min WS,Kang CS,Sim SI,Shin WS,Kim CC

    更新日期：2000-07-01 00:00:00

  • Evidence of alloreactive T lymphocytes in fetal liver: implications for fetal hematopoietic stem cell transplantation.

    abstract：:The use of hematopoietic stem cells for in utero transplantation to create permanent hematochimerism represents a new concept in fetal therapy, although this approach has provided heterogeneous results. In this paper we have undertaken molecular, phenotypic and functional studies aimed at identifying the presence of f...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702108

    authors： Renda MC,Fecarotta E,Dieli F,Markling L,Westgren M,Damiani G,Jakil C,Picciotto F,Maggio A

    更新日期：2000-01-01 00:00:00

  • Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation.

    abstract：:Infection with human cytomegalovirus (HCMV) after allogeneic bone marrow transplantation (BMT) was studied in 12 HCMV seronegative recipients of marrow from seropositive donors by weekly monitoring of cultures, expression of HCMV antigenemia (pp65) in granulocytes, polymerase chain reaction (PCR) on HCMV-DNA in granul...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： de Gast GC,Boland GJ,Vlieger AM,de Weger RA,Verdonck LF,Zwaan FE,Jiwa NM

    更新日期：1992-04-01 00:00:00

  • Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.

    abstract：:Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Morishima Y,Miyamura K,Kojima S,Ueda R,Morishita Y,Sao H,Tanimoto M,Ohno R,Sobue R,Hirano M

    更新日期：1993-04-01 00:00:00

  • Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.

    abstract：:Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma...

    journal_title：Bone marrow transplantation

    pub_type： 信件

    doi：10.1038/s41409-018-0112-x

    authors： Pandit A,Leblebjian H,Hammond SP,Laubach JP,Richardson PG,Baden LR,Marty FM,Issa NC

    更新日期：2018-07-01 00:00:00

  • Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors.

    abstract：:The role of ICU support in BMT patients is controversial. In an era of constrained resources, the use of prognostic factors predicting outcome may be helpful in identifying patients who are most likely (or unlikely) to benefit from this intervention. We attempted to define the survival of patients admitted to ICU foll...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701158

    authors： Jackson SR,Tweeddale MG,Barnett MJ,Spinelli JJ,Sutherland HJ,Reece DE,Klingemann HG,Nantel SH,Fung HC,Toze CL,Phillips GL,Shepherd JD

    更新日期：1998-04-01 00:00:00

  • Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

    abstract：:We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. IKZF1 deletions were identified in 93 patients (78.8%). IKZF1-deleted patients had a lowe...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2014.281

    authors： Kim M,Park J,Kim DW,Kim YJ,Jeon YW,Yoon JH,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim HJ,Min CK,Cho SG,Kim Y,Lee JW,Han K,Min WS,Lee S

    更新日期：2015-03-01 00:00:00

  • Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation.

    abstract：:We report a patient who developed a bone and adjacent soft tissue malignancy 22 months after bone marrow transplantation (BMT) for Philadelphia chromosome positive chronic myelogenous leukemia (CML). Concomitant bone marrow was cytologically and cytogenetically normal. Cytogenetic study of tumoral tissue was unsuccess...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Millot F,Facon T,Kerckaert JP,Fenaux P,Lai JL,Parent M,Bauters F,Jouet JP

    更新日期：1991-05-01 00:00:00

  • Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?

    abstract：:The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1703255

    authors： Sweetenham JW

    更新日期：2001-11-01 00:00:00

  • Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.

    abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some r...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705712

    authors： Smith SD,Bolwell BJ,Rybicki LA,Brown S,Dean R,Kalaycio M,Sobecks R,Andresen S,Hsi ED,Pohlman B,Sweetenham JW

    更新日期：2007-08-01 00:00:00

  • Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.

    abstract：:Autologous stem cell transplantation (ASCT) has an established role in the treatment of symptomatic multiple myeloma (MM). Our aim was to analyse the impact of selected prognostic parameters on the survival of patients with MM after ASCT. The new International Staging System (ISS) was also evaluated. A total of 133 MM...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704728

    authors： Krejci M,Buchler T,Hajek R,Svobodnik A,Krivanova A,Pour L,Adam Z,Mayer J,Vorlicek J

    更新日期：2005-01-01 00:00:00

  • Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.

    abstract：:One hundred and one donors who had received filgrastim (rhG-CSF) for the purpose of donating either granulocytes or peripheral blood stem cells (PBSC) for their relatives more than 3 years ago were contacted. All donors had received daily rhG-CSF at a median dose of 16 microg/kg/day (range 3-16) for a median of 6 days...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702072

    authors： Cavallaro AM,Lilleby K,Majolino I,Storb R,Appelbaum FR,Rowley SD,Bensinger WI

    更新日期：2000-01-01 00:00:00